Abstract 158P
Background
Single-cell RNA sequencing (scRNA-seq) has the ability to unveil uncommon cell populations. However, due to the high demand for tissue quality and cell viability, currently most scRNA-seq for pancreatic cancer was performed by surgical specimen or biopsy from metastatic sites. This study aims to establish a practical experience to help scientists perform primary pancreatic tumor scRNA-seq using EUS-FNB samples in real-world practice.
Methods
Two punctures from the same lesion using the same needle, without applying suction (Non-suction group) and with a negative pressure of 5 ml (Suction group) were evaluated. Single cell RNA sequencing libraries were prepared with Chromium Single cell 5’ Reagent Kits v2 (10X Genomics, USA) following the manufacturer’s protocol.
Results
A total of 20 patients were enrolled. The median age was 65.1 years old (range 46.6-83.2). Suction group achieved a cell preparation success rate of 80% (16/20) which was significantly higher than the 10% (2/20) success rate in the non-suction group (p<0.001). After the establishment of cell preparation protocol, we generate single-cell RNA transcriptomes for four patients, including two early stage (9,632 cells) and two late stage (4,592 cells). After quality control, 11,950 single cells were feasible for downstream analysis. Overall, 66% of cells (7,842) belonged to early stage and 34% (4,108) belonged to late stage. 12 major cell subtypes were identified across early and late stage. The proportion of cancer cells cluster-4 was significantly higher in late stage. Differentially expressed genes analysis showed UBE2C is the most highly expressed gene in cancer cells cluster-4. As external validation, in TCGA PAAD dataset, we found UBE2C high expression pancreatic cancer had significantly poor survival.
Conclusions
EUS-FNB with a negative pressure of 5 ml is feasible for single-cell sequencing in daily practice. A UBE2C high-expression subclone exists in early-stage pancreatic cancer and correlates with poor prognosis, potentially becoming a new therapeutic target in future studies.
Clinical trial identification
Protocol number: NCT05767697 Release date: 02 March, 2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Health Research Institutes.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract